Shares of Akcea Therapeutics Inc (NASDAQ:AKCA) have been given a consensus rating of “Hold” by the eight brokerages that are presently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $40.50.
A number of research firms have weighed in on AKCA. Zacks Investment Research upgraded AtriCure from a “hold” rating to a “buy” rating and set a $35.00 target price on the stock in a report on Monday. ValuEngine upgraded Xylem from a “hold” rating to a “buy” rating in a report on Tuesday, April 23rd.
Several hedge funds have recently bought and sold shares of AKCA. Rhumbline Advisers boosted its position in shares of Akcea Therapeutics by 2.4% in the 1st quarter. Rhumbline Advisers now owns 17,159 shares of the company’s stock worth $486,000 after purchasing an additional 409 shares in the last quarter. First Trust Advisors LP boosted its position in shares of Akcea Therapeutics by 0.6% in the 1st quarter. First Trust Advisors LP now owns 74,954 shares of the company’s stock worth $2,123,000 after purchasing an additional 460 shares in the last quarter. Squarepoint Ops LLC boosted its position in shares of Akcea Therapeutics by 9.8% in the 4th quarter. Squarepoint Ops LLC now owns 13,502 shares of the company’s stock worth $407,000 after purchasing an additional 1,202 shares in the last quarter. SG Americas Securities LLC boosted its position in shares of Akcea Therapeutics by 47.6% in the 1st quarter. SG Americas Securities LLC now owns 5,677 shares of the company’s stock worth $161,000 after purchasing an additional 1,831 shares in the last quarter. Finally, Quantamental Technologies LLC bought a new stake in shares of Akcea Therapeutics in the 1st quarter worth approximately $74,000. Hedge funds and other institutional investors own 25.30% of the company’s stock.
Shares of NASDAQ AKCA traded down $1.86 during midday trading on Monday, reaching $23.48. The company had a trading volume of 172,611 shares, compared to its average volume of 224,253. Akcea Therapeutics has a one year low of $19.67 and a one year high of $40.75. The company has a market cap of $2.32 billion, a PE ratio of -8.57 and a beta of 1.57. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.61 and a current ratio of 6.61. The company’s fifty day simple moving average is $22.64.
Akcea Therapeutics (NASDAQ:AKCA) last announced its quarterly earnings results on Wednesday, May 8th. The company reported $0.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.24 by ($0.90). Akcea Therapeutics had a negative net margin of 79.88% and a negative return on equity of 54.63%. The business had revenue of $163.82 million for the quarter, compared to analysts’ expectations of $171.40 million. During the same quarter in the prior year, the firm earned ($0.44) EPS. The firm’s revenue for the quarter was up 857.5% on a year-over-year basis. As a group, research analysts anticipate that Akcea Therapeutics will post -0.63 earnings per share for the current fiscal year.
Akcea Therapeutics Company Profile
Akcea Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy.
Featured Article: Investing in Growth Stocks
Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.